Management of Mosaic Karyotype 45,X/48,XXXX/46,XX

Initial Cardiovascular Assessment

The American College of Cardiology recommends comprehensive cardiovascular evaluation with baseline cardiac MRI and transthoracic echocardiography for individuals with mosaic karyotype 45,X/48,XXXX/46,XX, due to the presence of 45,X cells conferring Turner syndrome-related cardiovascular risks, including aortic dissection, regardless of the presence of normal 46,XX cells 1, 2
The detection of 45,X cells in 21% of the karyotype mandates Turner syndrome cardiovascular protocols, even with the majority normal 46,XX cells (73%) and rare 48,XXXX cells (6%), with a strength of evidence level of high 2, 3

Transthoracic echocardiography (TTE) is required to evaluate for bicuspid aortic valve (present in 15-30% of Turner syndrome), aortic coarctation (7-18%), and ascending aortic dilation, with a moderate level of evidence 1, 2
Cardiac MRI is necessary at diagnosis to measure aortic diameters precisely and identify congenital cardiovascular abnormalities that may be missed on TTE, with a high level of evidence 1, 3

For individuals ≥15 years old, calculate the aortic size index (ASI) to account for typically smaller body size in Turner syndrome mosaicism, with a moderate level of evidence 1, 2, 3
ASI = aortic diameter (mm) / body surface area (m²), with a high level of evidence 2
Alternative: aortic height index (AHI) = aortic diameter (mm) / height (m), with a moderate level of evidence 4, 3

Low risk (ASI ≤2.0 cm/m²): No additional cardiovascular risk factors, with a low level of evidence 3
Moderate risk (ASI 2.0-2.3 cm/m²): Requires closer surveillance, with a moderate level of evidence 2
High risk (ASI >2.3 cm/m²): Significantly increased dissection risk, with a high level of evidence 1, 3

Without additional risk factors: Children should undergo TTE or cardiac MRI every 5 years, and adults every 10 years, with a moderate level of evidence 2, 3
With ASI >2.3 cm/m²: At least annual surveillance imaging is required, with a high level of evidence 1, 2

Prophylactic aortic root/ascending aorta replacement is reasonable when ASI ≥2.5 cm/m² PLUS any of the following risk factors: bicuspid aortic valve, aortic coarctation, uncontrolled hypertension, rapid aortic growth (>3 mm/year), or planned pregnancy, with a high level of evidence 1, 2, 3

Hypertension control is critical: Treat aggressively according to general guidelines, with a high level of evidence 2, 3
Beta-blockers and/or angiotensin receptor blockers (ARBs) should be considered to inhibit aortic growth, similar to Marfan syndrome management, with a moderate level of evidence 2, 3

Mandatory pre-conception evaluation includes complete cardiovascular assessment with cardiac MRI measuring aortic dimensions, ASI calculation with risk stratification, and cardiology and maternal-fetal medicine consultation, with a high level of evidence 2, 3, 5, 6
Pregnancy is contraindicated if ASI >2.5 cm/m², any significant aortic dilation, bicuspid aortic valve with any aortic enlargement, aortic coarctation, or uncontrolled hypertension, with a high level of evidence 2, 3

Encourage regular physical activity but modify based on cardiovascular status and aortic dimensions, with a moderate level of evidence 1, 3
Avoid contact sports and isometric exercises if ASI >2.0 cm/m² or any cardiovascular abnormalities present, with a moderate level of evidence 3

Offer genetic counseling addressing low recurrence risk for phenotypically normal parents, implications of mosaic karyotype for health surveillance, and reproductive risks and options, with a moderate level of evidence 2, 3